NKTX
Nkarta, Inc.
$2.86
+3.62%
$204.6M
No data for this timeframe.
Vol
Market Cap$204.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders50 funds
Inst. Value$68.1M
Inst. Activity8 buys / 4 sells
Reddit Sentiment67° Warm
SEC Reports5
Press Releases2
Recent Activity
Jun 10, 2026
Insider
Thedinga Angela was granted 37,000 shares
Director
Jun 10, 2026
Insider
PATTERSON LEONE D was granted 37,000 shares
Director
Jun 10, 2026
Insider
Dybbs Michael was granted 37,000 shares
Director
May 12, 2026
SEC
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FD
PRESS-RELEASE — Impact 4/10
May 12, 2026
earnings
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
<p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a cl
Apr 15, 2026
Press
Nkarta announced FDA agreement on protocol amendments for its Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing,
Impact 7/10
Apr 6, 2026
SEC
Nkarta, Inc. (NKTX) has an S-3 shelf registration that became effective on April 3, 2026, allowing the company to raise
EFFECT — Impact 7/10
Mar 26, 2026
SEC
Nkarta, Inc. announced an at-the-market (ATM) offering program allowing it to sell up to $100 million in common stock th
8-K — Impact 6/10
Price Targets
$11.20
+291.6% upside
Strong Buy
Current $2.86
Low $9.00
Median $11.00
High $16.00
5 analysts
$9.00
$16.00
Analyst Ratings
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Needham | REITERATE | Buy → Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 26, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.38 | $-0.39 — $-0.36 | -21% YoY | 2 |
| Next Q | $-0.39 ▲ +2.5% | $-0.41 — $-0.36 | -33% YoY | 2 |
| Current FY | $-1.52 ▲ +1.0% | $-1.60 — $-1.44 | -8% YoY | 2 |
| Next FY | $-1.73 ▲ +3.6% | $-1.95 — $-1.50 | -13% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
4/10
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FD
May 12, 2026
BULLISH
Press
7/10
Nkarta announced FDA agreement on protocol amendments for its Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing,
Apr 15, 2026
BEARISH
EFFECT
7/10
Nkarta, Inc. (NKTX) has an S-3 shelf registration that became effective on April 3, 2026, allowing the company to raise
Apr 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $22.8M | — |
| BlackRock, Inc. | $9.5M | — |
| Alyeska Investment Group, L.P. | $4.4M | — |
| TWO SIGMA INVESTMENTS, LP | $4.3M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Thedinga Angela | A | $0.00 |
| Jun 10, 2026 | PATTERSON LEONE | A | $0.00 |
| Jun 10, 2026 | Dybbs Michael | A | $0.00 |
| Jun 10, 2026 | Scheiner Zachary | A | $0.00 |
| Jun 10, 2026 | Vratsanos George | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $68.1M total value (32,280,948 shares) as of 2026-Q1. Top holders: RA, BlackRock,, Alyeska. Net buying activity: 8 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 10,805,129 | $22.8M | 33.5% | — |
| 2 | BlackRock, Inc. | 4,508,473 | $9.5M | 14.0% | — |
| 3 | Alyeska Investment Group, L.P. | 2,084,840 | $4.4M | 6.5% | — |
| 4 | TWO SIGMA INVESTMENTS, LP | 2,047,376 | $4.3M | 6.3% | ADD +86.9% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,011,421 | $4.2M | 6.2% | — |
| 6 | CITADEL ADVISORS LLC | 1,783,994 | $3.8M | 5.5% | — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 1,732,372 | $3.7M | 5.4% | ADD +48.6% |
| 8 | WASATCH ADVISORS LP | 1,577,847 | $3.3M | 4.9% | — |
| 9 | STATE STREET CORP | 1,237,474 | $2.6M | 3.8% | — |
| 10 | Nuveen, LLC | 445,798 | $940.6K | 1.4% | DOUBLED +133.8% |
| 11 | GOLDMAN SACHS GROUP INC | 385,000 | $812.3K | 1.2% | — |
| 12 | D. E. Shaw & Co., Inc. | 356,932 | $753.1K | 1.1% | — |
| 13 | DIMENSIONAL FUND ADVISORS LP | 346,593 | $730.9K | 1.1% | ADD +74.4% |
| 14 | VANGUARD FIDUCIARY TRUST CO | 328,040 | $692.2K | 1.0% | — |
| 15 | MORGAN STANLEY | 313,054 | $660.5K | 1.0% | TRIM -34.3% |
| 16 | PANAGORA ASSET MANAGEMENT INC | 284,210 | $599.7K | 0.9% | ADD +56.5% |
| 17 | VANGUARD PORTFOLIO MANAGEMENT LLC | 272,079 | $574.1K | 0.8% | — |
| 18 | Woodline Partners LP | 168,110 | $354.7K | 0.5% | TRIM -33.0% |
| 19 | Invesco Ltd. | 150,940 | $318.5K | 0.5% | ADD +28.8% |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 130,975 | $276.4K | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Nuveen, LLC | DOUBLED | 190,683 | 445,798 | +133.8% | $940.6K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 198,699 | 346,593 | +74.4% | $730.9K | 2026-Q1 |
| Woodline Partners LP | TRIM | 250,848 | 168,110 | -33.0% | $354.7K | 2026-Q1 |
| DEUTSCHE BANK AG\ | DOUBLED | 2,115 | 76,627 | +3523.0% | $161.7K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 142,835 | 68,305 | -52.2% | $144.1K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 110,019 | 53,442 | -51.4% | $112.8K | 2026-Q1 |
| CWM, LLC | ADD | 23,274 | 42,632 | +83.2% | $90.0K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 22,898 | 40,046 | +74.9% | $84.5K | 2026-Q1 |
| Mariner, LLC | DOUBLED | 13,151 | 34,274 | +160.6% | $72.2K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 14,998 | 23,531 | +56.9% | $54.6K | 2026-Q1 |
| HSBC HOLDINGS PLC | NEAR_EXIT | 161,434 | 12,034 | -92.5% | $25.4K | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 4,420 | 5,620 | +27.1% | $11.9K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,145,077 | 1,702,022 | +48.6% | $3.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 520,172 | 971,982 | +86.9% | $1.8M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 473,217 | 311,116 | -34.3% | $575.6K | 2025-Q4 |
| PANAGORA ASSET MANAGEMENT INC | ADD | 181,600 | 284,210 | +56.5% | $525.8K | 2025-Q4 |
| Woodline Partners LP | TRIM | 375,166 | 250,848 | -33.1% | $464.1K | 2025-Q4 |
| Nuveen, LLC | ADD | 95,563 | 190,683 | +99.5% | $352.8K | 2025-Q4 |
| HSBC HOLDINGS PLC | ADD | 94,955 | 161,434 | +70.0% | $299.5K | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 84,914 | 155,036 | +82.6% | $286.8K | 2025-Q4 |
| Invesco Ltd. | ADD | 116,844 | 150,476 | +28.8% | $278.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 442,493 | 110,019 | -75.1% | $203.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 32,918 | 47,997 | +45.8% | $88.8K | 2025-Q4 |
| Cerity Partners LLC | TRIM | 33,240 | 23,394 | -29.6% | $43.3K | 2025-Q4 |
| Vanguard Personalized Indexing Management, LLC | TRIM | 30,338 | 20,895 | -31.1% | $38.7K | 2025-Q4 |
8 unique insiders with 8 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Thedinga Angela | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | PATTERSON LEONE D | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | Dybbs Michael | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | Scheiner Zachary | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | Vratsanos George | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | George Simeon | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | Behbahani Ali | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 37,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
NEUTRAL
PRESS-RELEASE
4/10
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The co
May 12, 2026
BEARISH
EFFECT
7/10
Nkarta, Inc. (NKTX) has an S-3 shelf registration that became effective on April 3, 2026, allowing t
Apr 6, 2026
BEARISH
8-K
6/10
Nkarta, Inc. announced an at-the-market (ATM) offering program allowing it to sell up to $100 millio
Mar 26, 2026
BEARISH
S-3
7/10
Nkarta, Inc. (NKTX) has filed a shelf registration (S-3) to raise up to $350 million, including $100
Mar 25, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.20 mean target
+291.6% upside
Strong Buy (3.00)
$9.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $2.86 |
| Target Low | $9.00 |
| Target Mean | $11.20 |
| Target Median | $11.00 |
| Target High | $16.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.38 | $-0.39 | $-0.36 | -21.0% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.39 | $-0.41 | $-0.36 | -32.8% | +2.5% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-1.52 | $-1.60 | $-1.44 | -7.8% | +1.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.73 | $-1.95 | $-1.50 | -13.5% | +3.6% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.375 | |
| 7d ago | $-0.375 | |
| 30d ago | $-0.375 | |
| 60d ago | $-0.320 | -0.055 |
| 90d ago | $-0.320 | -0.055 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 26, 2026 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 12, 2026
earnings
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
<p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engi
May 12, 2026
earnings_calendar
NKTX Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
earnings_calendar
NKTX Q1 2026 Earnings Scheduled — 2026-05-07
Apr 15, 2026
fda
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
<p>SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing en
Mar 25, 2026
earnings
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
<p>SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing e
Mar 19, 2026
earnings_calendar
NKTX Q4 2025 Earnings After Market Close — 2026-03-19